INFQ Shorts Rebuild as Borrow Tightens on Quantum Rally

Infleqtion, Inc. heads into the final week of September with short sellers rebuilding positions into a 11% weekly rally — and the borrow market tightening sharply around them.

The positioning story is the most interesting tension here. Short interest climbed nearly 8% on the week to roughly 24.5 million shares, reversing a month-long decline that had briefly pulled the position count down from late-August highs above 26 million. What makes the rebuild notable is the backdrop: the stock just posted an 11% weekly gain to $14.06, yet bears are adding, not retreating. Borrow availability has halved in the past week — dropping from around 31% to 15% — meaning the lending pool is tightening fast even as new shorts enter. Availability has been as low as 0.6% in early September, so the market has seen extreme tightness before; it is moving back in that direction. Cost to borrow is modest at around 1.2%, well below the 2.7% peak seen in August, which tells you the squeeze pressure is not yet acute — but direction matters more than level right now.

Options traders are also turning more cautious than usual. The put/call ratio has climbed to 0.36, nearly two standard deviations above its 20-day average of 0.31, and sits at its highest level since late August. The reading is still far from extreme in absolute terms — the 52-week high is 0.90 — but the move is directionally consistent with the short rebuild: both signals point to hedging activity rather than outright conviction on either side.

The Street remains constructive on Infleqtion at a fundamental level. Six analysts carry buy-equivalent ratings with a mean price target of $21.33 — implying roughly 52% upside from current levels. B. Riley initiated with a $23 buy target on September 4. Citigroup raised its target to $22 from $20 in August. Wedbush and Canaccord both carry buy-equivalent ratings in the $20-22 range. The analyst community has been initiating coverage in clusters, which reflects the stock's relative novelty as a listed quantum-technology name rather than a deeply-researched consensus. With the stock trading at a negative P/E and EV/EBITDA — Infleqtion is pre-profitability — multiples are not the frame; revenue visibility and execution milestones are what analysts are watching.

The activist register adds another layer of complexity. Churchill Sponsor X LLC holds a 13D position on Infleqtion — an activist-intent filing that is among the most newsworthy structural facts about this stock. The filing history shows Churchill's disclosed stake sitting at approximately 4.9% as of a February 2026 amendment, down from 20.4% at the time of an earlier disclosure. MCV Management, another 13D filer, has trimmed from 9.2% to 3.6% as of a May 2026 amendment. Positions are as-last-disclosed around the 5% threshold, and holders dropping below 5% can exit without a further filing — so the picture may already look different. BlackRock and State Street both appear as recent institutional entrants in the August reporting window, which suggests index-eligible demand is growing alongside the speculative base. Separately, Maverick Capital — listed as a director-affiliated filer — sold approximately $2.1 million of stock in a single session on August 21, a discretionary sale (no 10b5-1 plan declared), while also purchasing roughly $647,000 worth of shares the week prior. The net 90-day insider position is sharply negative at around -10 million shares, though the bulk of that reflects the institutional reduction rather than executive-level conviction selling.

The next earnings event is scheduled for November 12. The two most recent prints both produced positive single-day moves — the August report generated a 10% one-day gain and a 16% five-day gain, while the prior print moved roughly 3% day-one. With the ORTEX short score at 67.5 and trending up across the past two weeks, and peers QUBT and SMCI each posting 15-16% weekly gains, the next focal point is whether Infleqtion can sustain its relative catch-up into the November print — or whether the short rebuild proves prescient first.